Evidence map›Paper›PMID 41847993›Full record

GuidelineJournal of the European Academy of Dermatology and Venereology : JEADV2026

Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short version.

Alexander Nast, Bassel H Al Wattar, Marie Beylot Barry, Holger Brüggemann, Zrinka Bukvić Mokos, Dawn M Caruana, Klaus Degitz, Clio Dessinioti, Brigitte Dréno, Rieke J B Driessen and 13 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Alexander NastDivision of Evidence-Based Medicine, Klinik für Dermatologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0003-3504-2203
Bassel H Al WattarComprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK.
Marie Beylot BarryDermatology Department, CHU Bordeaux, Bordeaux, France.ORCID https://orcid.org/0000-0001-6150-1229
Holger BrüggemannDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0000-0001-7433-0190
Zrinka Bukvić MokosDepartment of Dermatology and Venereology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia.
Dawn M CaruanaPrivate Practice, Valletta, Malta.
Klaus DegitzDepartment of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany.
Clio DessiniotiDepartment of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-4832-3410
Brigitte DrénoINSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes Université, Nantes, France.ORCID https://orcid.org/0000-0001-5574-5825
Rieke J B DriessenDepartment of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Harald GollnickDepartment of Dermatology and Venereology, University of Magdeburg, Magdeburg, Germany.ORCID https://orcid.org/0000-0003-1178-1765
Merete HædersdalDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Alexander KatoulisSecond Department of Dermatology and Venereology, Medical School, "Attikon" General University Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-8189-7486
Severin LäuchliInstitute of Dermatology and Venerology, Stadtspital Zürich, Zürich, Switzerland.
Julien LambertDepartment of Dermatology, University Hospital of Antwerp, University of Antwerp, Antwerp, Belgium.
Alison M LaytonSkin Research Centre, Hull York Medical School, University of York, York, UK.
Giuseppe MicaliDepartment of Dermatology, University of Catania, Sicily, Italy.ORCID https://orcid.org/0000-0002-5157-3939
Falk R OchsendorfDepartment of Dermatology, Venereology and Allergology, Goethe-University Frankfurt, Universitätsmedizin, Frankfurt, Germany.
Thozhukat SathyapalanDepartment of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK.
Katarina Zak StangelandDepartment of Dermatology and Venereology, Aleris Stavanger, Stavanger, Norway.
Simon Francis ThomsenDepartment of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Daniel TöröcsikDepartment of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Antonia PennitzDivision of Evidence-Based Medicine, Klinik für Dermatologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This evidence- and consensus-based guideline for the treatment of acne was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. This guideline is an update of the 2016 version. This is a short summary of the full version of the EuroGuiDerm Evidence-based Guideline for the Treatment of Acne. For the complete guideline text, detailed methods report, and comprehensive evidence report, please refer to the online full version. In this targeted update, the guideline group prioritized three key clinical questions considered most relevant for current practice: (a) For which types of acne and patient groups should isotretinoin be recommended versus systemic antibiotics, and with what strength of recommendation? (b) What is the appropriate duration for systemic antibiotic therapy? For which types of acne and patient groups should hormonal treatments and spironolactone be recommended, and with what strength of recommendation? For which types of acne and patient groups should new topical treatments, including trifarotene and clascoterone, be recommended and with what strength of recommendation? Additionally, the updated guideline provides revised recommendations regarding: safety of benzoyl peroxide (BPO), selection of systemic antibiotic therapy, treatment considerations during pregnancy, isotretinoin dosing strategies, and the use of hormonal antiandrogenic contraceptives or other combined hormonal contraceptives, as well as spironolactone. All other aspects remain unchanged from the 2016 guideline.

Indexed as

Acne VulgarisAnti-Bacterial AgentsDermatologic AgentsBenzoyl PeroxideEvidence-Based MedicineFemaleHumansIsotretinoinPregnancySpironolactoneAnti-Bacterial AgentsBenzoyl PeroxideDermatologic AgentsIsotretinoinSpironolactoneacne vulgarisevidence‐based medicinemethodsoral administrationpractice guidelinetopical administration

Identifiers

PMID41847993
PMCPMC13308670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.